Business Context and Reporting Period
Company: ClearOne, Inc. (CLRO)
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2026
Reporting Period: The filing reports on events occurring on August 7, 2026, with agreements effective retroactively to June 1, 2026.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the execution of material definitive agreements involving equity compensation.
Material Changes and Agreements
On August 7, 2026, the Company entered into Advisor Agreements with four entities to compensate them for past and ongoing advisory services. The agreements are linked to an Agreement and Plan of Merger dated July 1, 2026, involving CLRO Merger Sub, Inc., Cortigent, Inc., and Vivani Medical, Inc.
- First Finance Ltd.: Awarded 25,000 shares of Common Stock. (Note: First Finance Ltd. is a majority stockholder of the Company).
- Betelgeuse Capital Advisors Inc.: Awarded 90,000 shares of Common Stock.
- Gang3 Capital Ltd.: Awarded 140,000 shares of Common Stock. (Note: Eric Boehnke, a director since June 20, 2025, exercises voting power over these shares).
- JJK Holdings Ltd.: Awarded 600,000 shares of Common Stock.
Total Shares Issued: 855,000 shares of Common Stock ($0.001 par value).
Term: Agreements are effective as of June 1, 2026, and continue until the completion of services or upon ten business days' prior written notice by the Advisor.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary regarding future performance. The primary context provided is the connection of these advisor agreements to a pending merger transaction. No specific risks or contingencies are detailed beyond the standard terms of the advisory agreements.
Key Facts for Investor Verification
- Equity Dilution: Verify the impact of issuing 855,000 new shares on existing shareholder ownership percentages.
- Related Party Transactions: Confirm the extent of First Finance Ltd.'s majority ownership and Eric Boehnke's control over Gang3 Capital Ltd. shares to assess potential conflicts of interest.
- Merger Status: Investigate the current status of the Agreement and Plan of Merger with Cortigent, Inc. and Vivani Medical, Inc., as these agreements are tied to that transaction.
- Valuation: Determine the fair market value of the shares issued as compensation, as the filing does not state the share price at the time of issuance.